(ALC) Alcon - SW
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: SW (Switzerland) | Market Cap: 25.926m CHF | Total Return: -24.6% in 12m
Avg Turnover: 72.0M
EPS Trend: -15.3%
Qual. Beats: 0
Rev. Trend: 99.1%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Alcon AG is a global leader in the ophthalmology sector, specializing in the development and manufacture of surgical equipment and vision care products. The company’s Surgical segment provides a comprehensive suite of technologies for cataract, vitreoretinal, and refractive procedures, including intraocular lenses (IOLs) and advanced visualization systems. The Vision Care segment focuses on consumer-oriented products, such as daily disposable contact lenses and ocular health solutions for dry eye and glaucoma.
The business model relies on a razor-and-blade strategy, where the sale of high-margin surgical consoles and diagnostic equipment drives recurring revenue through specialized consumables and procedure packs. The ophthalmic equipment industry is characterized by high barriers to entry due to stringent regulatory requirements and the intensive R&D investment necessary to maintain technological parity in micro-surgical instrumentation.
For a deeper dive into the companys valuation metrics and historical performance, consider reviewing the detailed analytics available on ValueRay.
Alcon operates as a large-cap entity within the Health Care Equipment sub-industry, maintaining its headquarters in Geneva, Switzerland. Since its founding in 1945, the firm has expanded its portfolio to include digital health platforms and cloud-based diagnostic tools to integrate surgical workflows.
- Advanced IOL adoption drives Surgical segment revenue and margin expansion
- Contact lens innovation and price mix fuel Vision Care growth
- R&D investment in Unity platform secures long-term competitive positioning
- Emerging market expansion offsets mature market pricing pressures and competition
| Net Income: 816.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.14 > 1.0 |
| NWC/Revenue: 34.22% < 20% (prev 38.50%; Δ -4.27% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.27b > Net Income 816.6m |
| Net Debt (4.12b) to EBITDA (2.65b): 1.55 < 3 |
| Current Ratio: 2.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (490.2m) vs 12m ago -1.57% < -2% |
| Gross Margin: 55.36% > 18% (prev 55.55%; Δ -0.19% > 0.5%) |
| Asset Turnover: 33.79% > 50% (prev 32.01%; Δ 1.78% > 0%) |
| Interest Coverage Ratio: 6.32 > 6 (EBIT TTM 1.30b / Interest Expense TTM 206.3m) |
| DSRI: 1.02 (Receivables 2.02b/1.86b, Revenue 10.6b/9.93b) |
| GMI: 1.00 (GM 55.55% / 55.36%) |
| AQI: 0.97 (AQ_t 0.63 / AQ_t-1 0.65) |
| SGI: 1.07 (Revenue 10.6b / 9.93b) |
| TATA: -0.05 (NI 816.6m - CFO 2.27b) / TA 31.7b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of June 19, 2026, the stock is trading at CHF 51.90 with a total of 1,846,971 shares traded.
Over the past week, the price has changed by -2.09%,
over one month by +2.18%,
over three months by -13.73% and
over the past year by -24.64%.
Alcon has no consensus analysts rating.
Market Cap USD = 32.4b (25.9b CHF * 1.2511 CHF.USD)
P/E Trailing = 39.9699
P/E Forward = 19.2678
P/S = 2.438
P/B = 1.4578
P/EG = 1.4942
Revenue TTM = 10.6b USD
EBIT TTM = 1.30b USD
EBITDA TTM = 2.65b USD
Long Term Debt = 4.16b USD (from longTermDebt, last quarter)
Short Term Debt = 648.0m USD (from shortTermDebt, last quarter)
Debt = 5.78b USD (from shortLongTermDebtTotal, last quarter) + Leases 528.0m
Net Debt = 4.12b USD (calculated: Debt 5.78b - CCE 1.66b)
Enterprise Value = 36.6b USD (32.4b + Debt 5.78b - CCE 1.66b)
Interest Coverage Ratio = 6.32 (Ebit TTM 1.30b / Interest Expense TTM 206.3m)
EV/FCF = 21.43x (Enterprise Value 36.6b / FCF TTM 1.71b)
FCF Yield = 4.67% (FCF TTM 1.71b / Enterprise Value 36.6b)
FCF Margin = 16.10% (FCF TTM 1.71b / Revenue TTM 10.6b)
Net Margin = 7.71% (Net Income TTM 816.6m / Revenue TTM 10.6b)
Gross Margin = 55.36% ((Revenue TTM 10.6b - Cost of Revenue TTM 4.73b) / Revenue TTM)
Gross Margin QoQ = 56.36% (prev 55.78%)
Tobins Q-Ratio = 1.15 (Enterprise Value 36.6b / Total Assets 31.7b)
Interest Expense / Debt = 3.57% (Interest Expense 206.3m / Debt 5.78b)
Taxrate = 16.92% (166.3m / 982.9m)
NOPAT = 1.08b (EBIT 1.30b * (1 - 16.92%))
Current Ratio = 2.20 (Total Current Assets 6.64b / Total Current Liabilities 3.01b)
Debt / Equity = 0.26 (Debt 5.78b / totalStockholderEquity, last quarter 22.2b)
Debt / EBITDA = 1.55 (Net Debt 4.12b / EBITDA 2.65b)
Debt / FCF = 2.41 (Net Debt 4.12b / FCF TTM 1.71b)
Total Stockholder Equity = 22.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.60% (Net Income 816.6m / Total Assets 31.7b)
RoE = 3.70% (Net Income TTM 816.6m / Total Stockholder Equity 22.1b)
RoCE = 4.97% (EBIT 1.30b / Capital Employed (Equity 22.1b + L.T.Debt 4.16b))
RoIC = 3.76% (NOPAT 1.08b / Invested Capital 28.8b)
WACC = 6.20% (E(32.4b)/V(38.2b) * Re(6.78%) + D(5.78b)/V(38.2b) * Rd(3.57%) * (1-Tc(0.17)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -20.0 | Cagr: -0.56%
[DCF] Terminal Value 76.08% ; FCFF base≈1.67b ; Y1≈1.75b ; Y5≈2.01b
[DCF] Fair Price = 55.14 (EV 31.0b - Net Debt 4.12b = Equity 26.9b / Shares 487.7m; r=8.35% [WACC [floored]]; 5y FCF grow 4.99% → 2.50% )
EPS Correlation: -15.29 | EPS CAGR: -1.84% | SUE: 0.69 | # QB: 0
Revenue Correlation: 99.06 | Revenue CAGR: 5.17% | SUE: -0.32 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.76 | Chg30d=-0.63% | Revisions=-38% | Analysts=15
EPS next Quarter (2026-09-30): EPS=0.56 | Chg30d=+0.00% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=3.47 | Chg30d=+0.03% | Revisions=+65% | GrowthEPS=+12.9% | GrowthRev=+7.0%
EPS next Year (2027-12-31): EPS=4.38 | Chg30d=+0.82% | Revisions=+48% | GrowthEPS=+26.2% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: +65%